Breaking Research News from sources other than Breastcancer.org
Comments
-
Fifteen Things Physicians and Patients Should Question
https://www.aafp.org/dam/AAFP/documents/about_us/i...0 -
'World-first' call for exercise to be prescribed to all Australian cancer patients
0 -
Obamacare Premiums to Surge Next Year, Early Requests Show
https://www.bloomberg.com/news/articles/2018-05-07...
{disturbing}
0 -
Global Analysis of Advanced/Metastatic Breast Cancer: Decade Report (2005–2015)
TAKE-HOME MESSAGE
- Using results from four global qualitative and quantitative surveys of nearly 15,000 patients in 34 countries as well as a literature review, the authors provide an overview of metastatic breast cancer care gaps, resources, and support available for patients in different regions of the world. Modest outcome improvements have been reported over the last decade. However, patients still do not receive adequate information. Furthermore, quality of life may have declined over the past decade.
- A global effort of healthcare professionals, patients, families, and advocates is needed to improve patient outcomes and quality of life.
https://www.practiceupdate.com/c/67169/67/13/?elsc...
0 -
Time Trends of Overall Survival Among Metastatic Breast Cancer Patients in the Real-Life ESME Cohort
TAKE-HOME MESSAGE
- In this French, multicenter observational cohort of 15,085 patients with newly diagnosed metastatic breast cancer and full immunohistochemistry data, the authors evaluated the impact of year of diagnosis on overall survival. Of these patients, 9907 were HR+/HER2−, 2861 were HER2+, and 2317 were HR−/HER2−. The entire cohort had a median overall survival of 37.22 months. Year of diagnosis, age, subtype, disease-free interval, visceral metastases, and number of involved organs were independent predictors of overall survival. Year of diagnosis was a strong predictor of overall survival in HER2+ patients, but not in HR+/HER2− or HR−/HER2− patients.
- These data demonstrate improved overall survival in patients with HER2+ metastatic breast cancer, highlighting the need for new strategies for other subtypes.
- RESULTS: Median OS of the whole cohort was 37.22 months (95% confidence interval [CI], 36.3-38.04). Year of diagnosis was an independent predictor of OS (hazard ratio 0.98 [95% CI, 0.97-1.00], P = .01) together with age, subtype, disease-free interval, visceral metastases and number of organs involved. Median OS of HR+/HER2-, HER2+ and HR-/HER2- subcohorts was, respectively, 42.12 (95% CI, 40.90-43.10), 44.91 (95% CI, 42.51-47.90) and 14.52 (95% CI, 13.70-15.24) months. Year of diagnosis was a strong independent predictor of OS in HER2+ subcohort (hazard ratio 0.91 [95% CI, 0.88-0.94], P < .001), but not in HR+/HER2- nor HR-/HER2- subcohorts (hazard ratio 1.00 [95% CI, 0.98-1.01], P = .80 and 1.00 [95% CI, 0.97-1.02], P = .90, respectively).
0 -
Intrathecal Administration of Trastuzumab Is Feasible in Patients With HER2+ Breast Carcinomatous Meningitis
TAKE-HOME MESSAGE
- In this phase I dose-escalation study, 16 patients with leptomeningeal carcinomatosis from HER2+ breast cancer received intrathecal trastuzumab. No dose-limiting toxicity of trastuzumab was observed. Of these patients, 11 did not exhibit toxicities attributable to trastuzumab. Minor toxicities attributable to trastuzumab at 60-mg or higher dose levels included headache, nausea, vomiting, cervical pain, and peripheral neuropathy. Clinical responses were achieved in 3 patients, 7 had stable disease, and 4 had progressive disease.
- The recommended phase II weekly dose of intrathecal trastuzumab is 150 mg in patients with HER2+ breast cancer.
0 -
A Serum MicroRNA Signature Predicts Trastuzumab Benefit in HER2+ MBC
TAKE-HOME MESSAGE
- In this study, a miRNA microarray identified 13 miRNAs in the serum of patients with HER2+ metastatic breast cancer with a distinct response to trastuzumab treatment. Of these, four miRNAs (miR-940, miR-451a, miR-16-5p, and miR-17-3p) were used to create a signature predictive of survival using a LASSO model. These miRNAs are directly involved in regulating resistance to trastuzumab.
- This miRNA signature, which may predict trastuzumab benefit in patients with HER2+ metastatic breast cancer, warrants further validation in prospective clinical trials.
https://www.practiceupdate.com/c/67476/67/13/?elsc...
Abstract - Published: 24 April 2018:
https://www.nature.com/articles/s41467-018-03537-w
{This study was done in China. It's very new. Really interesting, IMO. Would be interested to hear if anyone's MO team has mentioned this in discussion. Thx.}
0 -
Lumpie - fascinating series of posts. Z
0 -
Hopeful8201: Thanks for posting about "Breast Cancer Info Scrubbed From Government Website." That is, indeed, disturbing.
0 -
Pressure to stay positive may be a negative for cancer patients
0 -
Exploring vitamin D metabolism and function in cancer
0 -
"The All of Us Research Program has a simple mission. We want to speed up health research breakthroughs. To do this, we're asking one million people to share health information. In the future, researchers can use this to conduct thousands of health studies."
https://www.joinallofus.org/en
0 -
I can't recall if we shared this before, but this would be a great tool for all surgeries! I wonder if any of our members have participated with a trial.
Light up malignant cells during surgery with infrared lighting.
0 -
The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. pub date: 2018 Apr 11
Abstract:
0 -
UTA researcher patents "roach motel" for cancer
0 -
Invasive cancers that are born to be bad show detectable differences from harmless tumors
0 -
ASCO: 2018 Treatment Algorithm for Metastatic HER2-Positive Breast Cancer
0 -
Hi Lumpie,
Thank you so much for all your work in posting these studies. I greatly appreciate it. How are you doing and feeling these days?
May you be well.
0 -
Hi couragement! I'm a little obsessive (but also a little random) with the research and reading... and how much I can do varies with my workload... but if I am finding interesting stuff, I figure I might as well share it!
I had an infusion yesterday. The last couple of times I have been so tired, i slept through 90% of it... which is not bad. Besides some fatigue and a few misc side effects, I am doing pretty well these days - thanks for asking. I have a scan coming up. Fingers crossed. Hope you are doing well. Thanks for reading. If you find any interesting articles, please share.
0 -
Israeli researchers say they have found a way to curb growth of cancer cells
0 -
Glyphosate shown to disrupt microbiome 'at safe levels', study claims
Study on rats said to show that the chemical, found in Monsanto's Roundup weedkiller, poses 'a significant public health concern'
https://www.theguardian.com/environment/2018/may/1...
{troubling}
0 -
Study Finds More Isn't Better for Widely Used Breast Cancer Drug
...women with a dangerous form of breast cancer have relied on Roche Holding AG's blockbuster drug Herceptin, taking the $76,700-a-year medicine for 12 months to fight off the disease. A new study finds that they may be able to cut their treatment in half.
https://www.bloomberg.com/news/articles/2018-05-16...
Same topic, NY Times:
https://mobile.nytimes.com/2018/05/16/health/breas...
0 -
This new beer is developed specifically for breast cancer patients
https://www.fastcompany.com/40572691/this-new-beer...
{Wonder if they'd wanna fund some meaningful research....?}
0 -
0
-
A group of us did research on NSAIDS, Blocks, and opioids the summer of 2015 It resulted in four thread that are all linked to each other. This is the link to the NSAIDS thread. Specifically, Ketorolac (Toradol).
https://community.breastcancer.org/forum/73/topics...The next link is a composite thread for combining the info to take to docs for discussion.
https://community.breastcancer.org/forum/26/topics...
Dr V's video is an excellent presentation on how NSAIDS help prevent mets
0 -
These couple of articles are on gut health and the brain
https://community.breastcancer.org/forum/73/topics...
0 -
Too busy battling brain lesion of unknown provenance to comment in substance, but to everyone posting, I get a lot of ideas from this thread. Thanks, Z
0 -
Distressed to hear about your brain lesion of unknown provenance, zarovka! Take care - hope it improves! -Lumpie
0 -
TKI Inhibitors for Brain Metastases in HER2+ Breast Cancer
https://www.practiceupdate.com/c/68007/67/13/?elsc...
TAKE-HOME MESSAGE
- There are few active systemic therapies for patients with brain metastases in HER2+ breast cancer. TKI inhibitors represent a viable option in these patients, and the addition of capecitabine strongly enhances their efficacy.
- Patients with brain metastases should not be excluded from clinical trials.
0 -
The Availability and Effectiveness of Tools Supporting Shared Decision Making in Metastatic Breast Cancer Care: A Review
https://www.practiceupdate.com/c/68101/67/13/?elsc...
TAKE-HOME MESSAGE
- These authors conducted a review to assess the availability and effectiveness of tools that support shared decision-making in the context of metastatic breast cancer care. In all seven tools were identified, three focused on metastatic cancer in general and four were developed specifically to support shared decision-making in metastatic breast cancer. All were designed to be used by the patient prior to consultation with the physician. Only two of the tools received positive evaluations in terms of effectiveness, and, although promising, the authors suggest that their effectiveness be confirmed in studies prior to use in practice.
- The authors also suggest that tools be developed that target physicians in addition to patients for use during the clinical encounter.
0
